Business Context and Reporting Period
This Form 8-K is a current report filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on July 27, 2022. The registrant is a Delaware corporation with principal executive offices in Palo Alto, California. The filing serves as a Regulation FD disclosure regarding a specific scientific development.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a disclosure of a non-financial event.
Material Changes
The material event disclosed is the awarding of a grant to a team led by researchers at the University of Oxford by the National Institute for Health and Care Research (NIHR) in the U.K. The grant is intended to fund a feasibility trial investigating anti-tumor necrosis factor (TNF) therapy.
Guidance, Outlook, and Risks
- Outlook: The press release incorporated by reference contains forward-looking statements regarding the Company's expectations for the feasibility trial and future financial performance.
- Risks: The filing explicitly states that actual events and results may differ materially from projected statements due to known and unknown risks, uncertainties, and assumptions outside the Company's control.
- Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the specific scope and funding amount of the NIHR grant awarded to the University of Oxford team.
- Confirm the Company's specific role and ownership rights regarding the anti-TNF therapy feasibility trial.
- Review the full text of the press release (Exhibit 99.1) for detailed forward-looking statements and risk factors.
- Check subsequent filings (10-Q or 10-K) for any financial impact or progress updates on this trial.